摘要BACKGROUND Sacubitril-valsartan has been shown to reduce hospitalizations and mortality in patients with heart failure (HF) and reduced ejection fraction. The PIONEER-HF trial demonstrated that initiation of the drug during acute HF hospitaliza-tion reduced NT-proBNP levels and a post-hoc analysis of the trial found a reduction in HF hospitalizations and deaths. Real-life studies in the elderly population are scarce. The aim of our study was to assess the effectiveness of sacubitril-valsartan versusan-giotensin converting enzymeinhibitors (ACEI) in elderly patients who initiate this treatment during hospitalization for acute HF. METHODS We conducted a retrospective cohort study using the Spanish acute heart failure registry (RICA) comparing rehos-pitalizations and deaths at 3 months and 1 year among patients aged 70 years or older who had initiated treatment with sacubitril-valsartan during hospitalization for acute HF versus those treated with ACEI.RESULTS One hundred and ninety-nine patients hospitalized between October 2016 and November 2020 were included, with a median age of 82 years and high rate of comorbidity. Of these, 107 were treated with sacubitril-valsartan and 92 with ACEI. The adjusted OR for readmission for HF at 3 months was 0.906 (95％ CI: 0.241–3.404) and for the combined variable readmission for HF or death at 3 months was 0.696 (95％ CI: 0.224–2.167). The adjusted OR for HF readmission at one year was 0.696 (95％ CI:0.224 –2.167). and for the combined variable HF readmission or death at one year 0.724 (95％ CI: 0.325–1.612). CONCLUSION Treatment with sacubitril-valsartan initiated early in hospitalization for HF in elderly patients with high co-morbidity was associated with a trend towards a reduction in readmissions and death due to HF compared to treatment with ACEI, which did not reach statistical significance either at 3 months or 1 year of follow-up.